CytomX Therapeutics, Inc.CTMXNASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +43.17% | +22.80% | -25.71% | -82.16% | -98.26% |
| Gross Profit Growth | +43.17% | +22.80% | -25.71% | -82.16% | -99.60% |
| EBITDA Growth | +0.00% | +89.76% | +0.00% | -409.19% | -251.57% |
| Operating Income Growth | +0.00% | +94.06% | +0.00% | -483.56% | -258.00% |
| Net Income Growth | +2155.20% | +70.58% | +0.00% | -348.06% | -240.44% |
| EPS Growth | +1835.48% | +58.82% | +0.00% | -233.53% | -170.83% |
| EPS Diluted Growth | +1835.48% | +58.82% | +0.00% | -233.73% | -170.83% |
| Weighted Average Shares Growth | +19.00% | +6.21% | +52.07% | +93.91% | +112.47% |
| Weighted Average Shares Diluted Growth | +19.00% | +5.47% | +52.07% | +93.66% | +112.47% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | -9.59% | -85.16% | -32.65% | -51.40% | -19.01% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | -40.27% | -46.67% | +9.95% | +13.87% | +26.52% |
| Book Value per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Debt Growth | -32.84% | -36.69% | -41.38% | -47.19% | -54.82% |
| R&D Expense Growth | -23.71% | -14.44% | -47.08% | -28.38% | +40.38% |
| SG&A Expenses Growth | -28.15% | +21.59% | -21.12% | -19.19% | +30.21% |